BUSINESS● LOW1h ago · Sep 8, 2026, 2:26 PM
Amgen drops on Novartis trial setback for heart therapy; BMO downgrades
Seeking Alpha Tech · global
Amgen's stock has fallen due to a trial setback for Novartis's heart therapy and a subsequent downgrade by BMO. This illustrates how news from a competitor can impact a company's market valuation.
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text.
More in Business
BUSINESS40m agoKartoon Studios' new business plan fails to win over investorsSeeking Alpha TechBUSINESS55m agoBessent Loads Bazooka As Oil Prices Rise, Treasury Yields WaverYahoo FinanceBUSINESS59m agoCorning Stock Climbs On Multibillion-Dollar Verizon Network DealYahoo FinanceBUSINESS59m agoAdobe (ADBE) Declines on Elevated Investor HopesYahoo Finance